Rameen Kasana
2 min read
In This Article:
NeuroPace, Inc. (NASDAQ:NPCE) is among the best NASDAQ stocks under $50 to buy. Cantor Fitzgerald reiterated its Overweight rating on NeuroPace, Inc. (NASDAQ:NPCE), with a price target of $16.00, implying an upside of nearly 44%. This affirmation is based on a survey of medical professionals about the giant’s RNS System.
The survey, conducted among 30 medical professionals, including epileptologists, neurologists, and neurosurgeons, assessed perceptions regarding the potential FDA approval and adoption of the RNS System for idiopathic generalized epilepsy (IGE). The results raised the firm’s confidence in NeuroPace, Inc. (NASDAQ:NPCE).
A close-up of a medical device being calibrated and tested in a clinical laboratory setting.
With a one-year return surpassing the market’s return by 60.82%, NeuroPace, Inc. (NASDAQ:NPCE) is certainly heading north. The company is developing responsive neurostimulation technology to detect specific brain activity patterns related to seizures. The current RNS System is approved for particular kinds of epilepsy, with the potential IGE indication highlighting its total addressable market (TAM).
NeuroPace, Inc. (NASDAQ:NPCE), founded in 1997, is a medical device company in the United States. The company develops RNS systems and provides physician tablets and patient data management systems. The company is aimed at transforming the lives of people living with epilepsy.
While we acknowledge the potential of NPCE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
